CLEVELAND — The Cleveland Clinic unveiled the 10 innovations they are looking forward to in 2020.
The list of up-and-coming technologies was selected by a panel of Cleveland Clinic physicians and scientists, led by Michael Roizen, M.D., Emeritus Chief Wellness Officer at Cleveland Clinic.
“Healthcare is ever changing and we anticipate that these innovations will significantly transform the medical field and improve care for patients at Cleveland Clinic and throughout the world,” said Dr. Roizen.
The Cleveland Clinic tweeted out their list on Wednesday.
No. 1: The FDA recently approved a dual-acting drug that can help patients with osteoporosis prevent additional fractures: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 2: A newly expanded indication for a minimally invasive heart valve repair device provides an important new treatment option: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 3: Recent FDA approval of the first-ever medication for transthyretin amyloid cardiomyopathy brings hope for those with a potentially fatal disorder: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 4: A new oral immunotherapy medication to gradually build tolerance to peanut exposure may improve protection against allergic reactions: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 5: Closed-loop spinal cord stimulation allows for better communication between the implanted device and the spine, optimizing stimulation and pain relief: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 6: Biologics are increasingly embraced in orthopaedic care for their ability to replace or harness the body’s own power to expedite healing: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 7: An antibiotic-embedded envelope used to encase implanted cardiac devices proves effective for preventing device infections: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 8: Bempedoic acid provides an alternative to statins for lowering LDL cholesterol: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 9: PARP inhibitors are being approved for first-line maintenance therapy in advanced-stage ovarian cancer after showing improvement in progression-free survival: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
No. 10: A class of medications used to treat type 2 diabetes is a potential new treatment option for heart failure with preserved ejection fraction: #MIS2019
— Cleveland Clinic MD (@CleClinicMD) October 23, 2019
Tweet
